Esperion Therapeutics (ESPR) recently caught my eye because of a newly announced 256% upside target from Needham. This article reflects my evaluation of Esperion as an investment vehicle.
Esperion Therapeutics is a small biotech with a tightly focused mission of lipid management
Esperion's founder, Roger Newton, was a leader in development of Pfizer's (PFE) Lipitor. He moved on from Pfizer and founded Esperion Therapeutics, which he later sold to Pfizer. Following the Great Recession, he worked a deal with Pfizer to spin out Esperion as a new startup.
In a 2013